A phase I trial investigating the safety and tolerability of single ascending doses of ALKS-7119 in healthy subjects

Trial Profile

A phase I trial investigating the safety and tolerability of single ascending doses of ALKS-7119 in healthy subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs ALKS 7119 (Primary)
  • Indications Agitation
  • Focus Adverse reactions; First in man
  • Sponsors Alkermes plc
  • Most Recent Events

    • 28 Apr 2016 Full results from this study, including unblinded safety data, are expected in the second half of 2016, according to an Alkermes media release.
    • 28 Apr 2016 Preliminary data from the first six escalating dose cohorts published in an Alkermes media release.
    • 25 Jan 2016 According to an Alkermes media release, results from this study are expected to be available in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top